相关实验视频

Updated: May 1, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

在评估1252个细胞学上不确定的甲状腺结节时,ThyroSeq,ThyGeNEXT/ThyraMIR和Afirma分子平台的性能特征

Courtney F Connelly¹, Marie C Smithgall¹, Niyati Desai¹

¹Department of Pathology and Cell Biology, NewYork-Presbyterian/Columbia University Irving Medical Center, New York, New York.

Journal of the American Society of Cytopathology

|May 17, 2025

概括

对具有不确定的细胞学的甲状腺结节的分子测试显示,在排除癌症方面,ThyroSeq,ThyGeNEXT/ThyraMIR和Afirma平台的疗效相似. 然而,这项研究的整体表现低于先前研究报告的水平.

科学领域:

内分泌学在内分泌学.
在瘤学瘤学.
分子诊断学分子诊断

背景情况:

甲状腺结节的手术前风险分层与不确定的细胞学是至关重要的.
分子诊断,包括基因型和表达特征分析,有助于评估术前癌症风险.
有几种商业分子平台可用于甲状腺结节评估.

研究的目的:

为了比较三个商业分子平台的诊断准确性:ThyroSeq,ThyGeNEXT/ThyraMIR和Afirma.
评估这些平台在细胞学上不确定的甲状腺结节的手术前风险分层中的有效性.
评估这些分子平台在1252个结节的队列中的性能特征.

主要方法:

对1252个细胞学上不确定的甲状腺结节进行了回顾性分析.
对三种分子诊断平台的评估:ThyroSeq,ThyGeNEXT/ThyraMIR和Afirma.
诊断准确度,灵敏度和负预测值的比较.

主要成果:

分子评估表明,28.7%的病例患有恶性瘤风险增加.
在209个切除的结节中,48.8%是恶性瘤.
甲状腺切除检测显示,在5.5%的阴性分子检测病例中出现瘤,其中59.2%为恶性.

结论:

甲状腺Seq,ThyGeNEXT/ThyraMIR和Afirma在排除无确定的甲状腺结节的恶性病症方面表现出类似的疗效.
敏感度分别为87.5%,66.7%和73.1%,负预测值为80.0%,70.0%和66.0%.
在这项研究中,这些平台的整体表现低于一些先前发表的研究结果.

关键词:

不确定的甲状腺结节.分子测试是分子测试.甲状腺是什么?甲状腺是什么?甲状腺细胞病理学甲状腺结节甲状腺结节

更多相关视频

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis

Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis

Published on: February 9, 2024

相关概念视频

Synthesis and Regulation of Thyroid Hormones

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...

Hyperthyroidism II: Pathophysiology

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...